COVID-19: Russian Vaccine Shows Signs Of Immune Response
Lancet study finds 100 percent of participants developed antibodies.
Results published in The Lancet journal on Friday showed that Russia’s COVID-19 vaccine, called Sputnik V, had managed to produce an antibody response in all participants in early-stage trials, without any side effects. These trials were conducted between June and July on 76 participants. However, the medical journal has warned that long-term trials were needed in order to determine the efficiency of the vaccine. “The two 42-day trials – including 38 healthy adults each – did not find any serious adverse effects among participants, and confirmed that the vaccine candidates elicit an antibody response,” the report read.
Russia had announced on August 11 that it has developed the world’s first vaccine against the coronavirus. Following this, it had faced criticism from scientists and experts for not conducting Phase 3 trials to determine its safety. The advanced trial for Sputnik V started last week, with the mayor of Moscow has called upon the city’s citizens to participate in the process. Over 3,000 people have apparently been recruited for the large-scale trial, with its results expected to come in October or November.
Get the latest COVID-19 updates only on ZEE5.